Geneious Biologics takes Next Generation antibody sequence analysis to Amsterdam

AUCKLAND, NZ – May 29, 2018 – Geneious Biologics software for antibody screening and discovery will exhibit during the Antibody Engineering & Therapeutics Europe conference at the Amsterdam Hilton from Tuesday, June 5 until Thursday, June 7.

Launched in May 2017, Geneious Biologics has rapidly built on its capability to handle large scale next generation sequencing (NGS) antibody data sets and accelerate screening and identification of therapeutic antibody candidates.

“Next generation informatics platforms like Geneious Biologics will accelerate the future of therapeutic antibody discovery,” said Vice President, Geneious Biologics Solutions, Jannick Bendtsen, PhD.

“We will be at the Antibody Engineering and Therapeutics conference in Amsterdam to demonstrate Geneious Biologics’ new capabilities for Sanger and NGS data analysis. We welcome everyone who is interested in a conversation about how Geneious Biologics can be deployed to develop therapeutic antibodies better and faster, to join us at Stand #15.”

About Geneious Biologics

Geneious Biologics is a next generation cloud software solution purpose-built, in collaboration with industry partners, for commercial antibody discovery and screening. Delivered through a modern intuitive, user-friendly web interface, the platform provides a fully managed data and informatics system in a secure cloud computing infrastructure.